Seleziona una pagina

CHI SIAMO

Atlas è l’atlante relativo alle mutazioni a carico dei geni che assumono il ruolo di biomarcatori per l’inquadramento clinico dei pazienti oncologici che rappresenta un aiuto nel comprendere il carattere predittivo di ogni specifica mutazione. Sistematizza le informazioni relative alle mutazionia carico di geni che assolvono il ruolo di biomarcatori predittivi positivi di risposta al trattamento nelle neoplasie solide riscontrate sia nella “real practice” che negli studi clinici per fornire uno strumento utile alla comunità di esperti per la corretta definizione del valore clinico di ogni singola mutazione.

L’ambito di azione di ATLAS riguarda le neoplasie solide dove la presenza di alterazioni del DNA rende il paziente eleggibile al trattamento con farmaci a bersaglio molecolare.

BOARD SCIENTIFICO

Il coordinamento delle attività dei due gruppi è affidato a un board scientifico.

s-novello

Prof.ssa Silvia Novello

Oncology Department, A.O.U San Luigi, University of Turin, Italy

MD, PhD is Full Professor of Medical Oncology in the Oncology Department at San Luigi Hospital in Orbassano, Italy, part of the University of Turin. She earned her medical degree and completed the postgraduate training in Respiratory Medicine and Medical Oncology at the University of Turin and partially at the Institut Gustave Roussy, in France. Currently, she is head of the Thoracic Oncology Unit at the San Luigi Hospital, Orbassano (Turin), where she also tutors medical students and Postgraduate students in Respiratory Medicine and Medical Oncology. 

Prof. Novello’s research interests include thoracic malignancies, primary prevention, gender differences in lung cancer, basic, translational and clinical applied research on lung cancer, including pharmacogenomics. She is involved as PI in many International and national controlled clinical trials evaluating new approaches in diagnosis and lung cancer therapy. From July 2012 until 2016, Prof Novello has been a Member of the Board of Directors of the International Association for the Study of Lung Cancer and since October 2016 Member of the Board of Directors of the Italian Association of Medical Oncology, past Secretary and now part of the EORTC Lung Cancer Group and member of several scientific societies including the American Society of Clinical Oncology, American Thoracic Society and the European Society of Medical Oncology.

Currently, she is the President of WALCE (Women Against Lung Cancer in Europe), a non profit European Association founded in 2006 in Turin, Italy, part of the scientific Committee of LuCe (Lung cancer Europe) and also member of the Scientific Committee of Bonnie J Addario Lung Cancer Foundation and Member of the Scientific Committee of ICAPEM (Investigación sobre Cáncer de Pulmón en Mujeres).

g-troncone

Prof. Giancarlo Troncone

Department of Public Health, University Federico II of Naples, Italy

MD, PhD, Full Professor of anatomic pathology, Director of the cytopathology unit, the molecular pathology unit, and the master’s degree program in predictive molecular pathology, Head of the Department of Public Health at the University of Naples Federico II in Naples, Italy. 

He was trained in pathology at the Nuffield Department of Pathology, University of Oxford (Oxford, United Kingdom), and in cytopathology at the Department of Pathology and Laboratory Medicine, University of Pennsylvania (Philadelphia). His research interests include the development, validation, and quality assessment of a wide range of morpho-molecular techniques on cytopathologic specimens in the field of predictive pathology of solid tumors. He maintains an active cytodiagnostic practice, which includes lung, thyroid, lymph node, and breast samples.

u-malapelle

Dr. Umberto Malapelle

Department of Public Health, University Federico II of Naples, Italy

PhD, Assistant Professor in Anatomic Pathology in School of Medicine, University of Naples Federico II.

Currently is the Chief Supervisor of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples.

His main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor.

Moreover, he has developed skills in tailoring Next Generation Assays for a number of different applications with a special focus on the simultaneously detection of clinical relevant alterations (i.e., EGFR mutations, ALK traslocation, PD–L1 expression) in the routine setting including handling of different sample types, such as tissues and/or liquid biopsy specimens.

CLINICI ESPERTI DEL GRUPPO LUNG

Dr. Diego Cortinovis

Oncology Unit ASST Monza, Ospedale San Gerardo, Monza

MD, since 2008, vice-director at the oncology unit and Head of Lung Unit at San Gerardo Hospital directed by Prof. Paolo Bidoli, in Monza, Italy, part of the University of Milan Bicocca. The first interest is clinical research focused in thoracic malignancies, lung cancer, mesothelioma, and supportive care. He’s Principal Investigator and Co-Investigator in different clinical trials since 2003. The primary interests are targeted therapies in non-small-cell lung cancer, new approaches in small-cell lung cancer and modern therapies in malignant pleural mesothelioma, as well as translational research related to predictive bio markers. He has been involved in different key trials investigating new approaches in treatment of advanced stage of disease like maintenance therapy, treatment with targeted therapies and immunotherapy as well as CINV. Finally he’s Co-author in many scientific papers, peer-reviewed journals and member of scientific journal boards and I’m member of different scientific societies including IASLC; ESMO; AIOT; AIOM.

u-malapelle
Dr. Domenico Galetta

Oncology Unit for Thoracic Diseases at Clinical Cancer Center IRCCS  “Giovanni Paolo II” Bari, Italy

Responsible of Medical Oncology Unit for Thoracic Diseases at Clinical Cancer Center IRCCS  “Giovanni Paolo II” Bari, Italy. Clinical assistance for both outpatient and inpatient at the Medical Oncology Department and scientific activity research focused mainly on patients with lung and pleural cancer. Degree in Medicine and Surgery, Specialization in Medical Oncology.

He began his clinical activity with an interest in lung and head and neck cancers. He subsequently perfected his experience on lung cancer with an internship at the Gustave Roussy Institute in Paris and by activating national and international collaborations.

He started the first existing thoracic oncology clinic in the Puglia region in 2010. This clinic currently evaluates 500 new patients per year. Invited as a speaker at numerous national and international congresses and conferences. He has participated since 1994 in all the International Conferences of the IASLC (World Lung Cancer Conference – International Association for the Study of Lung Cancer)

He was Principal investigator (or sub-investigator) of over 40 clinical trials on pleuropulmonary pathology, many of which were registrations for molecules subsequently registered in clinical practice. Currently, 22 clinical trials are active at the Clinical Cancer Center he directs. He is the author of 110 impacted publications. He is a member of the following scientific societies: American Society of Clinical Oncology (ASCO); European Society of Clinical Oncology (ESMO); Italian Association of Medical Oncology (AIOM), International Association for the Study of Lung Cancer

fabio-pagni-atlas
Dr. Fabio Pagni

SC Anatomia Patologica ASST Monza, Ospedale San Gerardo, Monza University Milano Bicocca

MD, he is Associate Professor at UNIMIB since 2019 where he performs as Director of the Residency Program in Pathology. He is an experienced pathologist, being responsible of the ultrasound-guided clinic for invasive Fine Needle Biopsy at ASST Monza, San Gerardo Hospital (catchment population of around 1000 personally performed biopsies / per year).

 

Fabio Pagni has spent the last five years improving his knowledge in proteomics and NGS to detect new diagnostic approaches to human cancer.

The potential correlation of the proteomics profiles with the genomic data could help in discriminating new diagnostic targets in oncology, potentially transferable in the routine practice. He is founder member of the Lung Unit, ASST, Monza.

 

Pagni was Principal Investigator of Italian and International grants. Hei has developed national and international collaborations, especially about the genetic characterization of human carcinomas’ related pathways.

He is author of around 110 PUBMED-indexed papers.

s-novello
Dr. Francesco Passiglia

Department of Oncology University of Turin, AOU San Luigi Gonzaga Hospital, Orbassano, Turin, Italy

MD, he is Assistant Professor at the Department of Oncology of the University of Turin, Italy. He is consultant at the Thoracic Oncology Unit of San Luigi Hospital, Orbassano (Turin), where he is daily dedicated to the diagnosis and treatment management of patients with thoracic malignancies. 

He is involved in international and national clinical trials as well as translational research projects mostly focusing on non-small cell lung cancer. Since October 2019 he is the scientific secretary of the Italian Association of Medical Oncology (AIOM) Lung Cancer Clinical Practice Guidelines. 

He is member of international scientific societies including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the International Association for the Study of Lung Cancer (IASLC).  

He is author or co-author of over 60 publications in peer-reviewed journals.

Dr.ssa Sara Pilotto

U.O.C. Oncology, University of Verona, University Hospital Trust of Verona, Italy

MD, PhD. Department: Oncology. Affiliation: U.O.C. Oncology, University of Verona, University Hospital Trust of Verona, Italy

Main Research/Clinical Interest Areas: clinical and translational research in lung cancer; prognostic and predictive models; methodology of clinical trials; comprehensive approach to cancer patient (i.e. nutrition, physical activity).

Dr. Pilotto is a medical oncologist, assistant professor at the University of Verona. She completed her graduate studies and residency in medical oncology with full marks and honors at the University Hospital Trust of Verona (Italy) and she trained in the Translational Research Unit at the Pangaea Biotech laboratory, Quiron-Dexeus University Hospital, Barcelona (Spain) thanks to a fellowship award of the International Association for Lung Cancer (IASLC) in 2015. In 2019, she completed her PhD in Inflammation, Immunity and Cancer at the University of Verona (Italy).

Dr. Pilotto is member of the Young investigators Lung Cancer Group of EORTC, of the Lung cancer Guidelines Experts Panel of Italian Association of Medical Oncology (AIOM) and member of the ESMO Press & Media Affairs Committee. She was reviewer for the Projects and/or Research Grants for IASLC (2017-2019) and member of the ESMO leadership program 2019.

u-malapelle
Dr.ssa Maria Lucia Reale

Department of Oncology, University of Turin, AOU San Luigi Gonzaga Hospital, Orbassano, Turin, Italy

After obtaining the graduation in Medicine in 2014, she started her fellowship in Oncology at the University of Turin, Italy. 

Her interest is mainly focused on clinical and research in thoracic oncology. Since 2019, she is Member of the board directors of the European Association Women Against Lung Cancer in Europe (WALCE). Patients’ needs, journey from diagnosis to treatments choice and management, attention to the quality of life, represent the pillars of her daily clinical activity. Commitment to research, participation in clinical trials, national and international scientific collaborations, are part of it, representing essential components to ensure the development and availability of more innovative, personalized and effective treatments.

g-troncone
Dr. Hector Soto Parra

Medical Oncology Department, “Azienda Ospedaliera Universitaria Policlinico-San Marco, Catania, Italy

MD, he is head of the Medical Oncology Department at the “Azienda Ospedaliera Universitaria Policlinico – San Marco”, Catania, Italy. He received his medical degree from the University of Zulia, Venezuela, in 1989, followed by a specialization in medical oncology in 1995 at the University of Milan. 

 

He was fellow and associated clinical research at Medical Oncology Department National Cancer Institute of Milan under the direction of Gianni Bonadonna and Associated Director of Medical Oncology at the Humanitas Cancer Center in Milan. 

 

His clinical and research activities has focused on lung cancer, mesothelioma and rare cancers, mainly adult sarcomas.  He has been involved in several studies for the development and testing of new targeted agents (NSCLC EGFR+, ALK+, PDGFA Sarcoma, breast cancer ) and participated in several phase II-III trials in lung cancer including with new immunotherapeutic  agents.  

 

Since July 2020 he leads the clinical trial unit of phase I studies in adults of the Policlinico San Marco Catania. 

s-novello
Dr. Marcello Tiseo

University Hospital of Parma, Italy

Prof. Marcello Tiseo achieved M.D. degree at the University of Pavia, Italy (score 110/110 cum laude) in July 20, 2001. From February 18, 2002 to November 8, 2005, he was fellow in Medical Oncology at the Department of Medical Oncology of the National Institute for Cancer Research of Genoa, Italy (Director: Prof. R. Rosso). In 2012 he performed a Professional Training at Medical Oncology Branch del National Cancer Institute di Bethesda (MD, US; Prof. G. Giaccone).

From 21 November 2005 to present, he is a Medical Oncologist at the Department of Medical Oncology of the University Hospital in Parma, Italy. From 09/2015: Coordinator of Thoracic Oncology Disease Management Team of the University Hospital of Parma, Italy. From 01/2018 Head of Day Hospital of Medical Oncology Unit, Azienda Ospedaliera-Universitaria di Parma.

From January 2008 to March 2012, PhD at University Hospital of Parma. From 1 November 2018, Associate Professor of Medical Oncology and Director of Specialty School of Oncology, University Hospital of Parma

From 02/2015 Scientific Secretary of Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). He is author or co-author of 250 papers in international peer-reviewed journals indexed by PubMed (H index = 35). He is a member of the Italian Association of Medical Oncology (AIOM), Italian Association of Thoracic Oncology (AIOT) and IASLC.

Prof. Tiseo has served as co-ordinator of several controlled clinical trials in NSCLC, SCLC and mesothelioma at national and international level. He was or is PI or co-investigator in research programs of Italian Ministry of Health or Regional Agency, project of Italian Drug Agency (AIFA) and research projects of AIRC (Italian Association for Cancer Research).

clinici esperti del gruppo delle neoplasie colon-rettali

Dr.ssa Chiara Cremolini

Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Italy

Chiara Cremolini is an Assistant Professor in Medical Oncology at the University of Pisa in Italy.

She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She is responsible for the scientific activities of the Clinical Trials’ Office at the Unit of Oncology at Santa Chiara Hospital in Pisa. She actively contributes to clinical trials by Gruppo Oncologico del Nord Ovest (GONO), an Italian Foundation involved in the design and conduction of clinical and translational studies in the field of several solid malignancies, serving as Scientific Secretary since 2015, and participates to the activity of the ESMO Faculty Member for the GI tumors.

She has been particularly involved in trials investigating intensified chemotherapy regimens as upfront treatment of metastatic colorectal cancer patients.

With regard to translational activities, she is mainly interested in the identification of molecular predictors of benefit from systemic treatments and to this purpose has tight collaborations with numerous international institutions. 

She is author of more than 150 papers in the field of colorectal cancer.

u-malapelle
Dr. Alfonso de Stefano

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy

Dr De Stefano is medical oncologist at Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples.
He works in the Experimental Clinical Abdominal Oncology Unit and his main field of clinical
activity is treatment of gastrointestinal malignancies, mainly colorectal, pancreatic and gastric
cancer. He is co-investigator and sub-investigator in several clinical trials and his research activity
is mainly focused on translational research for the definition of prognostic and predictive factors in
the treatment of metastatic colorectal cancer patients. He is co-author of several articles
published on peer-review journals and member of local and international societies of medical
oncology.

g-troncone
Dr. Filippo Pietrantonio

Department of Oncology and Hemato-Oncology of University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori (INT) of Milan, Italy

He is Assistant Professor at the Department of Oncology and Hemato-Oncology of University of Milan and medical doctor at Fondazione IRCCS Istituto Nazionale dei Tumori (INT) of Milan. He graduated in Medicine at the University of Parma in 2006 and undertook my medical oncology training followed by consulting activity at INT. He is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and their Team is deeply involved in the clinical and translational research in this field, thus collecting increasing relevance in the scientific community. His research interests are focused on the identification of molecular predictors of benefit from systemic treatments of colorectal and gastric cancer patients. His greatest efforts were spent in designing several ongoing no-profit clinical studies and translational projects. He is the author of 150 publications in peer-reviewed journals h-index 26. He acted as a reviewer for several specialized journals (i.e. Annals of Oncology, Cancer, JAMA, British Journal of Cancer, Cancer, European Journal of Cancer, Lancet Oncology, Cancer Research, Nature Reviews Clinical Oncology) and, since 2015 he is one of the section editors of Tumori Journal. He has given numerous international oral conference presentations and he is Member of AIOM, ESMO and EORTC.

s-novello
Dr. Andrea Sartore Bianchi

Clinical Molecular Oncology at the Department of Hematology & Oncology at Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, University of Milano (La Statale), Milan, Italy

He is head of Clinical Molecular Oncology at the Department of Hematology & Oncology at Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Associate Professor of Oncology at the University of Milano (La Statale), Milano, Italy. He completed his medical degree at the University of Pavia, Italy, and subsequently conducted preclinical research at the Division of Clinical Pharmacology and Experimental Cancer Therapeutics of the Department of Medicine at Brown University, Providence, RI, USA.

Dr. Sartore-Bianchi’s main clinical and research interests include the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to molecular-targeted therapies and on the epidermal growth factor receptor signal transduction pathway. He is principal and co-investigator in Phase I-III clinical trials for solid tumors and recently collaborated in the discovery and clinical development of targeted treatments for Her2-amplified colorectal cancer. He is first/corresponding author of research articles in various medical journals including Nature  Medicine, The Lancet Oncology, and Journal of Clinical Oncology. 

logo-bianco-rasatlas

Medica - Editoria e Diffusione scientifica

C.so Buenos Aires, 43 – 20124 Milano

02 76281337

info@medicacom.it

Powered & Design by Publics Icc